AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 21 min read$VSTM

Paterson Dan sold $353K of VSTM

Paterson Dan (President and CEO) sold 44,121 shares of Verastem, Inc. (VSTM) at $8.00 ($0.35M total) on 2026-10-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Paterson Dan
Published Oct 2, 2026, 9:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 9:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$VSTM
Bearish
medium confidence
Mentioned
$VSTM
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VSTMBearishLow
01

Why it matters

Provides fresh, primary‑source data on insider activity, useful for short‑term risk assessment.

02

Market read

Insider sale is a modest but material event for VSTM shareholders; limited broader market relevance.

03

What to watch

Potential upcoming clinical data releases may offset short‑term sell pressure.

Relevance 3/10Novelty 3/10Timing: today

Background

SEC Form 4 filing discloses an insider transaction by Verastem's CEO.

Company-level read

Ticker impact

$VSTMBearishMedium confidence
Context

Form 4 filing shows CEO sold 44,121 shares for $352,968, a direct insider sale via 10b5-1 plan.

Expected impact

likely slight pressure as the market prices in the insider sale

Evidence & confidence

Sale size is modest but involves the CEO; such transactions often prompt short-term selling pressure.

Market effects

Sector

Minimal impact on the biotech sector; insider sales are company‑specific.

Regional

No broader regional effect.

Global

Limited to investors tracking VSTM.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to fundamentals.

Key entities

  • company
    Verastem, Inc.

    Biotech firm listed on NASDAQ under ticker VSTM.

  • person
    Paterson Dan

    President and CEO of Verastem, filing the insider sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

VSTM insider trading history →

Related articles

OCT 28
$NVCRLowAI 8/10

Novocure partners with Verastem on pancreatic cancer trial

Novocure (NVCR) and Verastem Oncology (VSTM) partner to test Tumor Treating Fields therapy with VS-7375 for pancreatic cancer. Trial to start in 2027, focusing on safety and tolerability in 25 patients. Novocure will fund and manage the trial, while Verastem supplies the drug. The treatment aims to combine chemotherapy, VS-7375, and Tumor Treating Fields. Pancreatic cancer has a low survival rate and limited treatment options.

investing.com2 min
OCT 28
$NVCRLowAI 8/10

A planned trial will test electric-field therapy with chemotherapy and an experimental drug.

Novocure (NVCR) and Verastem Oncology plan a clinical trial to evaluate Tumor Treating Fields (TTFields) therapy with chemotherapy and Verastem’s experimental drug VS-7375 for locally advanced pancreatic cancer. The trial, expected to start in 2027, will assess safety and preliminary efficacy in about 25 patients. Novocure will manage and fund the trial, while Verastem will supply the drug. Both companies believe the combination could offer a new treatment approach for this challenging cancer.

stocktitan.net2 min
OCT 16
$VSTMHighAI 8/10

Wainwright reiterates Verastem stock rating on China trial data

H.C. Wainwright reiterated a Buy rating and $18.00 price target for Verastem (VSTM) after positive clinical trial data from China. The stock rose 10% last week to $9.23, up 46% in six months. GenFleet's data showed promising results for GFH375, the same molecule as Verastem's VS-7375, in colorectal and pancreatic cancer trials. Analysts maintain a strong buy consensus with targets ranging from $12 to $24.

investing.com2 min